Active Stocks
Thu Jun 27 2024 12:59:01
  1. Tata Steel share price
  2. 172.70 0.09%
  1. Power Grid Corporation Of India share price
  2. 329.45 0.80%
  1. Mahindra & Mahindra share price
  2. 2,848.40 -0.10%
  1. Infosys share price
  2. 1,566.85 1.65%
  1. State Bank Of India share price
  2. 844.00 -0.12%
Business News/ Markets / Stock Markets/  Thyrocare Technologies Q4 earnings: Net profit tumbles 36% to 21 Cr, revenue up 4%
BackBack

Thyrocare Technologies Q4 earnings: Net profit tumbles 36% to ₹21 Cr, revenue up 4%

During Tuesday's closing session, Thyrocare Technologies, a small-cap firm, registered a market cap of ₹2,487.45 Cr.

Thyrocare has 4 COVID labs in India, 3 zonal processing labs, 20+ regional processing labs in key metropolises, and 1 centralised processing laboratory in Navi Mumbai. (MINT_PRINT)Premium
Thyrocare has 4 COVID labs in India, 3 zonal processing labs, 20+ regional processing labs in key metropolises, and 1 centralised processing laboratory in Navi Mumbai. (MINT_PRINT)

During Tuesday's closing session, Thyrocare Technologies, a small-cap firm, registered a market cap of 2,487.45 Cr. The first and most sophisticated fully automated laboratory in India is Thyrocare Technologies Limited, which has a significant presence in more than 2000 Indian cities and towns. Thyrocare has 4 COVID labs in India, 3 zonal processing labs, 20+ regional processing labs in key metropolises, and 1 centralised processing laboratory in Navi Mumbai. Today, the company released its Q4 results. 

During Q4FY23, the company recorded revenue from operations of 135.88 Cr up by 4% YoY from 130.56 Cr in Q4FY22. The company said its EBITDA stood at 26.32 Cr during the quarter ended March 2023 compared to 37.89 Cr during the quarter ended March 2022. 

The net profit of Thyrocare Technologies stood at 13.71 Cr during the quarter under review down by 36% YoY from 21.46 Cr in the year-ago quarter. Its PAT margin dropped to 10% from 16% and its EBITDA margin dropped to 19% from 29%.

During the entire financial year FY23, the company said its revenue from operations stood at 526.67 Cr down by 11% YoY from 588.86 Cr in FY22. “Diagnostics revenue decreased 11% Y-o-Y in FY23 due to steep degrowth in COVID revenue (171 Cr in FY22 vs 6 Cr in FY23)," said Thyrocare Technologies. The company said its EBITDA stood at 122.09 Cr in 12MFY23 as against 234.79 Cr in 12MFY22. The net profit of the company plummeted by 63% YoY from 176.06 Cr in FY22 to 65.89 Cr in FY23. “Profit after Tax % lower due to non-cash items of ESOPs and provision for receivables," said Thyrocare Technologies in a statement.

The shares of Thyrocare Technologies closed today on the BSE at 469.95 apiece up by 2.05% from the previous close of 460.50.

3.6 Crore Indians visited in a single day choosing us as India's undisputed platform for General Election Results. Explore the latest updates here!

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less
Published: 23 May 2023, 06:01 PM IST
Next Story footLogo
Recommended For You
GENIE RECOMMENDS

Get the best recommendations on Stocks, Mutual Funds and more based on your Risk profile!

Let’s get started